;PMID: 2676145
;source_file_800.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..37] = [t:0..37]
;1)sentence:[e:42..91] = [t:42..91]
;2)section:[e:95..106] = [t:95..106]
;3)section:[e:110..221] = [t:110..221]
;4)sentence:[e:225..421] = [t:225..421]
;5)sentence:[e:422..621] = [t:422..621]
;6)sentence:[e:622..876] = [t:622..876]
;7)sentence:[e:877..987] = [t:877..987]
;8)section:[e:991..1035] = [t:991..1035]

;section 0 Span:0..37
;Cancer Res  1989 Oct 15;49(20):5530-3
(SEC
  (FRAG (NNP:[0..6] Cancer) (NNP:[7..10] Res) (CD:[12..16] 1989)
        (NNP:[17..20] Oct) (CD:[21..23] 15) (CC:[23..27] ;49-LRB-)
        (CD:[27..29] 20) (-RRB-:[29..30] -RRB-) (CD:[30..35] :5530)
        (::[35..36] -) (CD:[36..37] 3)))

;sentence 1 Span:42..91
;Activated N-ras oncogenes in human neuroblastoma.
;[52..57]:gene-rna:"N-ras"
;[77..90]:malignancy:"neuroblastoma"
(SENT
  (NP-HLN
    (NP (JJ:[42..51] Activated) (NN:[52..57] N-ras) (NNS:[58..67] oncogenes))
    (PP (IN:[68..70] in)
      (NP (JJ:[71..76] human) (NN:[77..90] neuroblastoma)))
    (.:[90..91] .)))

;section 2 Span:95..106
;Ireland CM.
(SEC
  (FRAG (NNP:[95..102] Ireland) (NNP:[103..105] CM) (.:[105..106] .)))

;section 3 Span:110..221
;Children's Leukemia and Cancer Research Unit, Prince of Wales Children's 
;Hospital, New South Wales, Australia.
(SEC
  (FRAG (NNP:[110..118] Children) (POS:[118..120] 's) (NNP:[121..129] Leukemia)
        (CC:[130..133] and) (NNP:[134..140] Cancer) (NNP:[141..149] Research)
        (NNP:[150..154] Unit) (,:[154..155] ,) (NNP:[156..162] Prince)
        (IN:[163..165] of) (NNP:[166..171] Wales) (NNP:[172..180] Children)
        (POS:[180..182] 's) (NNP:[184..192] Hospital) (,:[192..193] ,)
        (NNP:[194..197] New) (NNP:[198..203] South) (NNP:[204..209] Wales)
        (,:[209..210] ,) (NNP:[211..220] Australia) (.:[220..221] .)))

;sentence 4 Span:225..421
;Fifteen primary neuroblastomas and four bone marrow samples from
;neuroblastoma  patients, representing clinical Stages I to IV, have been
;screened for mutations  in codons 12, 13, and 61 of N-ras.
;[233..255]:malignancy:"primary neuroblastomas"
;[290..351]:malignancy:"neuroblastoma  patients, representing clinical Stages
;I to IV"
;[376..385]:variation-event:"mutations"
;[390..399]:variation-location:"codons 12"
;[390..396]...[409..411]:variation-location:"codons"..."61"
;[390..396]...[401..403]:variation-location:"codons"..."13"
;[415..420]:gene-rna:"N-ras"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (NP (CD:[225..232] Fifteen)
           (JJ:[233..240] primary) (NNS:[241..255] neuroblastomas))
        (CC:[256..259] and)
        (NP
          (NP (CD:[260..264] four)
            (NML (NN:[265..269] bone) (NN:[270..276] marrow))
            (NNS:[277..284] samples))
          (PP (IN:[285..289] from)
            (NP (NN:[290..303] neuroblastoma) (NNS:[305..313] patients)))))
      (,:[313..314] ,)
      (VP (VBG:[315..327] representing)
        (NP
          (NP (JJ:[328..336] clinical) (NNS:[337..343] Stages) (CD:[344..345] I))
          (PP (TO:[346..348] to)
            (NP (CD:[349..351] IV))))))
    (,:[351..352] ,)
    (VP (VBP:[353..357] have)
      (VP (VBN:[358..362] been)
        (VP (VBN:[363..371] screened)
          (NP-1 (-NONE-:[371..371] *))
          (PP-CLR (IN:[372..375] for)
            (NP
              (NP (NNS:[376..385] mutations))
              (PP-LOC (IN:[387..389] in)
                (NP
                  (NP
                    (NP
                      (NML-2 (NNS:[390..396] codons))
                      (CD:[397..399] 12))
                    (,:[399..400] ,)
                    (NP
                      (NML-2 (-NONE-:[400..400] *P*))
                      (CD:[401..403] 13))
                    (,:[403..404] ,) (CC:[405..408] and)
                    (NP
                      (NML-2 (-NONE-:[408..408] *P*))
                      (CD:[409..411] 61)))
                  (PP (IN:[412..414] of)
                    (NP (NN:[415..420] N-ras))))))))))
    (.:[420..421] .)))

;sentence 5 Span:422..621
;Neuroblastoma DNAs were subjected to the  polymerase chain reaction to
;amplify the relevant sequences and were then  hybridized with specific
;oligonucleotides to locate and identify point  mutations.
;[422..435]:malignancy:"Neuroblastoma"
;[464..474]:gene-protein:"polymerase"
;[604..620]:variation-type:"point  mutations"
(SENT
  (S
    (NP-SBJ-1 (NN:[422..435] Neuroblastoma) (NNS:[436..440] DNAs))
    (VP
      (VP (VBD:[441..445] were)
        (VP (VBN:[446..455] subjected)
          (NP-1 (-NONE-:[455..455] *))
          (PP (TO:[456..458] to)
            (NP (DT:[459..462] the) (NN:[464..474] polymerase)
                (NN:[475..480] chain) (NN:[481..489] reaction)))
          (S-PRP
            (NP-SBJ (-NONE-:[489..489] *))
            (VP (TO:[490..492] to)
              (VP (VB:[493..500] amplify)
                (NP (DT:[501..504] the) (JJ:[505..513] relevant)
                    (NNS:[514..523] sequences)))))))
      (CC:[524..527] and)
      (VP (VBD:[528..532] were)
        (ADVP (RB:[533..537] then))
        (VP (VBN:[539..549] hybridized)
          (NP-1 (-NONE-:[549..549] *))
          (PP (IN:[550..554] with)
            (NP (JJ:[555..563] specific) (NNS:[564..580] oligonucleotides)))
          (S-PRP
            (NP-SBJ (-NONE-:[580..580] *))
            (VP (TO:[581..583] to)
              (VP (VB:[584..590] locate) (CC:[591..594] and)
                  (VB:[595..603] identify)
                (NP (NN:[604..609] point) (NNS:[611..620] mutations))))))))
    (.:[620..621] .)))

;sentence 6 Span:622..876
;The results show that one Stage I tumor contained an N-ras gene that  was
;activated by a GC-CG transversion of the first base of codon 61, while in 
;one Stage II tumor, activation of N-ras involved a GC-CG transversion of the 
;first position of codon 13.
;[648..661]:malignancy:"Stage I tumor"
;[675..680]:gene-rna:"N-ras"
;[711..713]:variation-state-original:"GC"
;[714..716]:variation-state-altered:"CG"
;[717..729]:variation-type:"transversion"
;[737..759]:variation-location:"first base of codon 61"
;[775..789]:malignancy:"Stage II tumor"
;[805..810]:gene-rna:"N-ras"
;[822..824]:variation-state-original:"GC"
;[825..827]:variation-state-altered:"CG"
;[828..840]:variation-type:"transversion"
;[849..875]:variation-location:"first position of codon 13"
(SENT
  (S
    (NP-SBJ (DT:[622..625] The) (NNS:[626..633] results))
    (VP (VBP:[634..638] show)
      (SBAR (IN:[639..643] that)
        (S
          (NP-SBJ (CD:[644..647] one)
            
            (NML (NN:[648..653] Stage) (CD:[654..655] I))
            (NN:[656..661] tumor))
          (VP (VBD:[662..671] contained)
            (NP
              (NP (DT:[672..674] an) (NN:[675..680] N-ras) (NN:[681..685] gene))
              (SBAR
                (WHNP-1 (WDT:[686..690] that))
                (S
                  (NP-SBJ-1 (-NONE-:[690..690] *T*))
                  (VP (VBD:[692..695] was)
                    (VP (VBN:[696..705] activated)
                      (NP-1 (-NONE-:[705..705] *))
                      (PP (IN:[706..708] by)
                        (NP-LGS
                          (NP (DT:[709..710] a)
                            (NML
                              (NML (NN:[711..713] GC))
                              (PP (SYM:[713..714] -)
                                (NP (NN:[714..716] CG))))
                            (NN:[717..729] transversion))
                          (PP (IN:[730..732] of)
                            (NP
                              (NP (DT:[733..736] the) (JJ:[737..742] first)
                                  (NN:[743..747] base))
                              (PP (IN:[748..750] of)
                                (NP (NN:[751..756] codon) (CD:[757..759] 61)))))))
                      (,:[759..760] ,)
                      (SBAR-ADV (IN:[761..766] while)
                        (S
                          (PP-LOC (IN:[767..769] in)
                            (NP (CD:[771..774] one)
                              
                              (NML (NN:[775..780] Stage) (CD:[781..783] II))
                              (NN:[784..789] tumor)))
                          (,:[789..790] ,)
                          (NP-SBJ
                            (NP (NN:[791..801] activation))
                            (PP (IN:[802..804] of)
                              (NP (NN:[805..810] N-ras))))
                          (VP (VBD:[811..819] involved)
                            (NP
                              (NP (DT:[820..821] a)
                                (NML
                                  (NML (NN:[822..824] GC))
                                  (PP (SYM:[824..825] -)
                                    (NP (NN:[825..827] CG))))
                                (NN:[828..840] transversion))
                              (PP (IN:[841..843] of)
                                (NP
                                  (NP (DT:[844..847] the) (JJ:[849..854] first)
                                      (NN:[855..863] position))
                                  (PP (IN:[864..866] of)
                                    (NP (NN:[867..872] codon) (CD:[873..875] 13))))))))))))))))))
    (.:[875..876] .)))

;sentence 7 Span:877..987
;N-ras activations were not detected in the six Stage  III tumors and eight
;Stage IV tumors that were examined.
;[877..882]:gene-rna:"N-ras"
;[924..941]:malignancy:"Stage  III tumors"
;[952..967]:malignancy:"Stage IV tumors"
(SENT
  (S
    (NP-SBJ-1 (NN:[877..882] N-ras) (NNS:[883..894] activations))
    (VP (VBD:[895..899] were) (RB:[900..903] not)
      (VP (VBN:[904..912] detected)
        (NP-1 (-NONE-:[912..912] *))
        (PP (IN:[913..915] in)
          (NP
            (NP
              (NP (DT:[916..919] the) (CD:[920..923] six)
                
                (NML (NN:[924..929] Stage) (CD:[931..934] III))
                (NNS:[935..941] tumors))
              (CC:[942..945] and)
              (NP (CD:[946..951] eight)
                
                (NML (NN:[952..957] Stage) (CD:[958..960] IV))
                (NNS:[961..967] tumors)))
            (SBAR
              (WHNP-2 (WDT:[968..972] that))
              (S
                (NP-SBJ-2 (-NONE-:[972..972] *T*))
                (VP (VBD:[973..977] were)
                  (VP (VBN:[978..986] examined)
                    (NP-2 (-NONE-:[986..986] *))))))))))
    (.:[986..987] .)))

;section 8 Span:991..1035
;PMID: 2676145 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[991..995] PMID) (::[995..996] :) (CD:[997..1004] 2676145)
        (NN:[1005..1006] -LSB-) (NNP:[1006..1012] PubMed) (::[1013..1014] -)
        (NN:[1015..1022] indexed) (IN:[1023..1026] for)
        (NNP:[1027..1035] MEDLINE-RSB-)))
